<DOC>
	<DOCNO>NCT02339064</DOCNO>
	<brief_summary>This Phase 3 , multicenter , open-label , safety efficacy study continuous infusion apomorphine subject advance Parkinson 's Disease ( PD ) unable achieve adequate control despite optimized noninvasive therapy .</brief_summary>
	<brief_title>Infusion Apomorphine : Long-term Safety Study</brief_title>
	<detailed_description>This Phase 3 , multi center , open-label study ass long-term safety continuous infusion apomorphine advance Parkinson 's disease ( PD ) patient unable achieve adequate control despite optimized noninvasive therapy . Further , study assess clinical effectiveness continuous infusion apomorphine reduce `` '' time advance Parkinson 's disease patient assess clinical effectiveness continuous infusion apomorphine improve `` '' time without troublesome dyskinesia .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Advanced idiopathic PD consistent UK brain bank criterion Overall control unsatisfactory opinion Investigator subject despite optimal treatment noninvasive therapy , exception current APOKYN user , restrict 25 % total enrolled subject Experience `` '' period average ≥3.0 hour per wake day Other criterion discuss detail potential subject site Investigator Experience `` '' troublesome dyskinesia average ≥2 hour per day History deep brain stimulation , levodopacarbidopa intestinal gel surgery , surgical intervention treatment Parkinson 's disease study entry time subject 's participation study History hypersensitivity apomorphine hydrochloride ingredient APOKYN PFS , include sodium metabisulfite Known , suspect , plan pregnancy Recent history ( within past 12 month ) , strong potential , alcohol substance abuse Lifetime history impulsive/compulsive behavior primarily associate use dopamine agonist History previously treat current diagnosis malignant melanoma Exhibits certain sign symptom cardiovascular disease Other criterion discuss detail potential subject site Investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson 's disease ,</keyword>
	<keyword>apomorphine</keyword>
	<keyword>Apokyn</keyword>
	<keyword>dopamine agonist</keyword>
	<keyword>levodopa</keyword>
	<keyword>advanced</keyword>
	<keyword>PD</keyword>
	<keyword>carbidopa</keyword>
	<keyword>pramipexole</keyword>
	<keyword>ropinirole</keyword>
	<keyword>rotigotine</keyword>
	<keyword>MAO-B inhibitor</keyword>
	<keyword>COMT inhibitor</keyword>
	<keyword />
	<keyword>dyskinesia</keyword>
</DOC>